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Abstract
The histone deacetylase inhibitor (HDACI) butyroyloxymethyl diethylphosphate (AN-7) synergizes the cytotoxic effect of
doxorubicin (Dox) and anti-HER2 on mammary carcinoma cells while protecting normal cells against their insults. This study
investigated the concomitant changes occurring in heart tissue and tumors of mice bearing a subcutaneous 4T1 mammary
tumor following treatment with AN-7, Dox, or their combination. Dox or AN-7 alone led to inhibition of both tumor growth
and lung metastases, whereas their combination significantly increased their anticancer efficacy and attenuated Dox-
toxicity. Molecular analysis revealed that treatment with Dox, AN-7, and to a greater degree, AN-7 together with Dox
increased tumor levels of cH2AX, the marker for DNA double-strand breaks and decreased the expression of Rad51, a
protein needed for DNA repair. These events culminated in increased apoptosis, manifested by the appearance of
cytochrome-c in the cytosol. In the myocardium, Dox-induced cardiomyopathy was associated with an increase in cH2AX
expression and a reduction in Rad51 and MRE11 expression and increased apoptosis. The addition of AN-7 to the Dox
treatment protected the heart from Dox insults as was manifested by a decrease in cH2AX levels, an increase in Rad51 and
MRE11 expression, and a diminution of cytochrome-c release. Tumor fibrosis was high in untreated mice but diminished in
Dox- and AN-7-treated mice and was almost abrogated in AN-7+Dox-treated mice. By contrast, in the myocardium, Dox
alone induced a dramatic increase in fibrosis, and AN7+Dox attenuated it. The high expression levels of c-Kit, Ki-67, c-Myc,
lo-FGF, and VEGF in 4T1 tumors were significantly reduced by Dox or AN-7 and further attenuated by AN-7+Dox. In the
myocardium, Dox suppressed these markers, whereas AN-7+Dox restored their expression. In conclusion, the combination
of AN-7 and Dox results in two beneficial effects, improved anticancer efficacy and cardioprotection.
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Introduction
Targeting histone modifications for therapeutic purposes has
been extensively investigated [1]. Studies have shown that the
pharmacological inhibition of histone deacetylase (HDAC) activity
may be beneficial for a variety of diseases [2,3]. Our group has
developed and studied several histone deacetylase inhibitory
prodrugs of butyric acid, which release acids and aldehydes upon
intracellular hydrolytic degradation [4–6]. These compounds were
found to modulate gene expression and induce histone hyper-
acetylation and apoptosis of cancer cells in vitro and in vivo [7–9].
Butyroyloxymethyl-diethyl phosphate (AN-7), which releases
butyric acid, formaldehyde and phosphoric acid, was the most
potent of the prodrugs evaluated and displays significant in vivo
activity. At doses of 25–50 mg/kg, AN-7 inhibits tumor growth,
angiogenesis, and metastasis in several mouse cancer models
[9,10]. The main advantages of AN-7 are its specific activity
against cancer cells and its synergistic interaction with commonly
used anticancer agents, such as anthracyclines and antibodies
against epidermal growth factor receptor (HER)-2 [11,12].
Doxorubicin (Dox) is one of most effective drugs currently
available for the treatment of neoplastic diseases. However, its use
is complicated by dose-limiting cardiotoxicity and the develop-
ment of multi-drug resistance [13]. One of the contributors to
Dox-induced cardiotoxicity is the formation of reactive oxygen
species (ROS), a critical mediator of myocardial damage, which,
with time, can lead to cardiomyopathy leading to heart failure
[14].
We have shown that AN-7 attenuates Dox-activated increase in
reactive oxygen species (ROS)-dependent death of cardiomyo-
blasts and cardiotoxicity in mice. Conversely, in 4T1 mammary
carcinoma cells, AN-7 interacts synergistically with Dox to induce
ROS-dependent cell death [12,15]. These opposing effects of AN-
7 and Dox reflect the changes in the levels of phosphorylated
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There are also differences in the levels of c-Myc and angiogenic
factors. In an in vivo study of AN-7 (50 mg/kg thrice a week for 3
weeks) and Dox (a single dose of 20 mg/kg) combination, the
increased level of c-Myc in the heart was accompanied by an
increased expression of the hypoxia-inducible factor (HIF)-1a [12].
HIF-1a controls the transcription of pro-angiogenic and cardio-
protective factors, including vascular endothelial growth factor
(VEGF), VEGF receptor, erythropoietin, and heme-oxygenase
(HO-1) [16]. Accordingly, we observed that treatment of mice
with AN-7 and Dox, elevated HO-1 expression in the myocar-
dium and diminished blood levels of the pro-inflammatory
cytokines, tumor necrosis factor (TNF)-a and interferon-c [12].
AN-7 together with Dox treatment shows cell-type selective
changes of key proteins that are involved in the control of viability,
inflammation and angiogenesis. This demonstrates the specificity
of this treatment. After showing the in vitro effects, the next
important step was to demonstrate that these events occur
simultaneously in tumor bearing animals. In this study, we
explored the pro- and anti-survival changes, both the physiological
and molecular changes which take place concomitantly in the
tumors and the hearts of mice bearing 4T1 mammary tumors,
following treatments with either Dox or AN-7 or AN-7+Dox.
Materials and Methods
Compounds and reagents
AN-7 was synthesized as described [17]. Doxorubicin hydro-
chloride, 2 mg/mL, was obtained from Ebewe Pharma
Ges.m.b.H. (Unterach, Austria). The following antibodies were
used: goat polyclonal anti-MRE11 (meiotic recombination 11
homolog A of S. cerevisiae, Santa Cruz Biotechnology, Santa Cruz,
CA, USA); rabbit polyclonal antibodies for c-Myc (Cell Signaling,
ck USA), low molecular weight fibroblast growth factor (lo-FGF
Santa Cruz Biotechnology), HO-1 (Stressgen, Ann Arbor, MI,
USA), cytochrome-c, HDAC5 (Cell Signaling, Danvers, MA,
USA), HDAC1 (Sigma, St. Louis, MO, USA), c-Kit and Rad51
(Santa Cruz Biotechnology), Ki67 (Lab Vision, Fremont, CA,
USA); mouse monoclonal antibodies for phosphor-H2AX, Ser
139, (cH2AX) (BioLegend, San Diego, CA, USA), vascular
endothelial growth factor (VEGF, Santa Cruz Biotechnology),
thrombospondin -1 (TSP-1) (Lab Vision, Fremont, CA, USA),
HDAC2 (Abcam, Cambridge, UK), and actin (MP Biomedicals,
Aurora, Ohio, USA). Secondary antibodies: horseradish peroxi-
dase (HRP)-conjugated goat anti-rabbit IgG and HRP-goat anti-
mouse IgG (Jackson ImmunoResearch Laboratories, West Grove,
PA, USA); IRDyeH 680 goat anti-mouse or anti-rabbit IgG (LI-
COR Biosciences, Lincoln, NE, USA); biotinylated goat anti-
rabbit and anti-mouse IgG-B (Santa Cruz Biotechnology).
Cell cultures
The murine mammary carcinoma 4T1 (CRL-2539) and
embryonic rat immortalized heart H9C2 (CRL-1446) cell lines
were obtained from ATCC (Rockville, MD, USA). The U251 MG
human glioma cell line was obtained from the University of
California, San Francisco brain tissue bank, and normal human
astrocytes (NHA) were obtained from Lonza International, Basel,
Switzerland. Cells were grown in DMEM with 10% fetal calf
serum (FCS) and 2 mM L-glutamine. The astrocytes were grown
in ABM
TM Basal Medium and AGM
TM Bullet KitH (Lonza
International). All cells were grown in the presence of 100 units/
mL penicillin, 100 mg/mL streptomycin, 12.5 units/mL nystatin
(Biological Industries, Beit Haemek, Israel), and incubated in a
humidified atmosphere of 5% CO2 and 95% air at 37uC.
Cell viability was measured with a FluoStar fluorometer using
Hoechst fluorescent reagent at 390–460 nm [12].
Syngeneic murine 4T1 breast carcinoma metastatic
model
All animal experiments were conducted according to the NCI
Laboratory Animal Care Guidelines with the approval of the Tel
Aviv University Committee for Animal Experimentation and the
Israel Ministry of Health (permit number M-05-024).
Eight- to ten-week old female BALB/c mice (Harlan, Jerusalem,
Israel) were implanted subcutaneously (sc) with 4T1 mammary
carcinoma cells (5610
5). Tumor length (L) and width (W) were
measured twice weekly with a caliper, and volume was calculated
according to the formula: (LxW
2)/2.
Treatment commenced when the tumor volume reached 75–
180 mm
3 (,10 days). The mice were randomly divided into 4
equal (n=14/group) groups for treatment: vehicle control (saline);
ip Dox 5 mg/kg once weekly; po AN-7 50 mg/kg 3 times weekly;
ip Dox 5 mg/kg ip once weekly and po AN-7 50 mg/kg 3 times
weekly (AN-7+Dox). Untreated, non-bearing tumor naı ¨ve mice
were maintained under the same conditions. The experiment was
terminated after 25 days. The tumors, lungs and hearts were
harvested and weighed. Organs from 3 mice of each group were
preserved for immunohistochemistry (IHC) and the remaining
organs were frozen (280uC) for Western blot analyses.
Measurement of the Activity of HDAC classes I and II
Cells were seeded in 96-well plates (10610
3 cells/well, in
quadruplicates) in growth medium for 24 h and then treated as
indicated for 2 h in the presence of the HDAC substrate (Fluor de
Lys
TM), the reaction was terminated by the addition of the Fluor
de Lys
TM developer (Biomol) and 2 mM trichostatin A (TSA). All
of the above reagents were included in a kit for measuring
activities of HDAC classes I and II (AK-503, Biomol, Plymouth
Meeting, PA, USA). The % inhibition was calculated from the
ratio of the fluorescence (measured at 355 nm excitation and
460 nm emission) in the drug treated compared to the untreated
control culture.
Western blot
Tumors and hearts were homogenized (Polytron; Kinematica,
Lucerne, Switzerland) in lysis buffer [10]. Cells (2610
6 cells per
plate) were plated in100 mm plates for 24 h then treated as
specified and lysed. Protein levels in the samples were determined
with the BCA protein assay kit (Pierce, Rockford, IL USA) and
subjected to Western blot analyses with enhanced chemilumines-
cence to visualize cH2AX, HO-1, c-Myc, and TSP-1 bands [10].
The levels of HDAC1, HDAC2, HDAC5, Rad51 and MRE11
were determined using their specified primary antibodies followed
by the secondary antibody IgG IRDye 680DX (LI-COR
Biosciences). Each detected band was quantified using the Odyssey
Infrared Imaging System (LI-COR Biosciences) and normalized to
the level of actin in the corresponding lanes. The fold increase of a
specific protein was determined by the ratio of the band intensity
obtained from treated and untreated samples.
Immunohistochemistry
Tumors and hearts were removed, fixed in 4% paraformalde-
hyde for 24 h, washed with PBS, dehydrated in increasing alcohol
concentrations and embedded in paraffin. Paraffin-embedded
blocks were processed as described [10]. Avidin-biotin nonspecific
binding was prevented by a blocking kit, according to the
manufacturer’s protocol (Vector Laboratories, Burlingame, CA,
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the specified primary antibodies. The secondary antibodies were
biotin conjugated goat anti-rabbit IgG (Santa Cruz). Slides were
then stained with the ABC peroxidase system, developed with
diaminobenzidine (DAB) or Nova Red chromogene substrates
(Vector Laboratories) and counterstained with hematoxylin (Bio-
Optica, Milano, Italy). The slides were examined using an
Olympus BX 52 light microscope, and images were taken with
an Olympus DP50 digital camera system.
Picrosirius red staining
Slides of tumor and heart tissues were stained with 0.1%
Picrosirius red and 0.2% fast green FCF (Sigma), as described
[18].
Data analysis
The average drug concentrations causing a 50% reduction in
cell viability or HDAC activity (IC50) were determined from the
formula of the best-fitted curve of percent survival or activity
versus drug concentrations ($3 independent dose-response
titrations). A two-sided t-test between groups was performed using
the Excel package for Windows 2003 (Microsoft). Time to
treatment failure was estimated by Kaplan-Meir curves, and
differences in time to treatment failure between groups were
assessed with the log-rank test.
Results
AN-7 enhanced the anticancer efficacy of Dox and
reduced its cardiotoxicity in 4T1 mammary carcinoma
model
In preliminary studies to determine the efficacy and toxicity
range of Dox, mice were treated with saline or ip Dox at a dose of
3 or 5 mg/kg once weekly. We found that the 5 mg/kg dose of
Dox inhibited tumor progression significantly better than the
3 mg/kg dose (p,0.05). On day 14, tumors and hearts were
weighed and no difference in the mean body weight was detected
among the three groups, however, a significant increase in heart-
to-body-weight ratio (HW/BW) was measured in the 5 mg/kg
Dox group (Figure 1A, B). On the basis of these results, we selected
the dose of 5 mg/kg Dox to assess the anticancer and
cardioprotective effects of AN-7 in the combined treatment (AN-
7+Dox).
In the pivotal study, the treatment of the different groups was as
specified in Figure 1, C–F. Treatment failure was defined by two
criteria, a loss of $20% body weight or a tumor volume of
,2c m
3. The experiment was terminated on day 25 of drug
treatment when the mice of the control group failed. According to
the first criterion, in the Dox-treated group, 50% (n=7) of the
mice failed the treatment on day 19, and 79% (n=10) of them
failed treatment on day 25. By contrast, in the other treatment
groups, 100% (n=14) of the mice survived on day 25, with
acceptable body and tumor weights (Figure 1C).
The average HW/BW was significantly higher in the Dox-
treated group than in the other groups, suggesting myocardial
cardiomyopathy (p#0.007; Figure 1D). When the same regimen
of Dox was administered together with AN-7, there was no
increase in the HW/BW and no morbidity. These observations
support the notion that AN-7 imparted protection against Dox-
induced cardiotoxicity thus increasing the animals’ well-being.
Mean tumor weights at the experimental end-point were as
follows: vehicle-treated (untreated), 2.0560.2 g; Dox-treated (in
the 4 surviving mice), 1.360.3 g; AN-7-treated, 1.5260.1 g; AN-
7+Dox-treated, 0.7160.1 g. Mean tumor weight was significantly
higher in the vehicle-treated group than in the other groups
(p#0.05; Figure 1E,) and significantly lower in the AN-7+Dox-
treated group than in the other groups (p#0.05; Figure 1E).
The lungs, removed from the euthanized mice, were stained in
Bouin’s solution and metastatic lesions were scored double-blindly.
In the drug-treated groups the average numbers of lung lesions
scored were: 1564 in Dox-treated (n=4 that survived to the
experimental end-point); 14.963 in AN-7-treated (n=14); 8.162
AN-7+Dox-treated (n=14) and 87620 (n=14) in the vehicle
treated mice. In the latter group the average number of lung
lesions was significantly higher than in all of the treated groups
(p#0.001) and in the mice treated with AN-7+Dox it was the
lowest (p,0.05, Figure 1F).
The treatments’ effects on HDACs expression and cellular
activity in vitro
The direct effect of AN-7 on cellular HDAC activity was
evaluated by incubating the cells for 2 h with the cell-permeable
fluorometric substrate of HDAC classes I and II (Fluor de Lys
TM).
The highest level of inherent HDACs activity (in untreated cells),
measured in the human glioma U251 cells, was 10062%. Relative
to U251 cells, the activity in murine mammary carcinoma 4T1
cells was 8661%, in the immortalized embryonic rat heart H9C2
cells, 3762% and in NHA it was 2362%. A dose-response of AN-
7 HDACs inhibitory effect yielded in U251 cells an IC50 of
7165 mM and in 4T1 cells an IC50 of 7364 mM (Figure 2A). In
H9C2 and NHA, 50% inhibition was unattainable and 100 mMo f
AN-7 inhibited less than 20% of the basal HDACs activity in both
cell types. The estimated IC50 for H9C2 was 382620 mM and for
NHA was 295630 mM (Figure 2 B). Overall, these data
demonstrate that in the untreated cancer cells the basal activity
of HDAC classes I and II is significantly higher than in the
immortalized cells (H9C2) or in NHA (p, 0.0001). Moreover, the
HDAC inhibitory potency of AN-7, as evident in the IC50 values,
is at least 4-fold greater in cancer cells than in non-cancerous cells.
Treatment of U251, H9C2 cells and NHA with 50 mM AN-7
for 3 h showed (in a representative-reproducible experiment) that
the highest expression levels of HDAC 1and 2 of class I and
HDAC 5 of class II, were in U251 cells (Figure 2 C). These
observations suggest that the activity of the HDACs in different
cell types correlates with their level of expression. After 3 h of
treatment, AN-7 had no noticeable effect on the expression of
these enzymes therefore its inhibitory effect on their activity is
likely to be a direct one. After 24 h, AN-7 downregulated the
expression of these enzymes only in U251 but not in H9C2 cells or
in NHA (Figure 2 C). Prolonged exposure of U251cells to AN-7, in
addition to inhibiting these enzymes activity, also downregulated
their expression.
Previously, we have shown that AN-7 synergistically increased
Dox cytotoxicity against 4T1 cells, and conversely, it protected
cardiomyocytes against Dox toxicity [12]. In an attempt to
understand the basis for this disparity, we examined the manner
by which AN-7, Dox and AN-7+Dox affect the total cellular
activity of HDACs classes I and II in these cancerous and non-
cancerous cells. Inhibition of total cellular HDACs activity in 4T1
cells was 3365%, after 3 h with 50 mM AN-7, no inhibition after
2 h with 200 nM Dox and 5062% after 3 h with AN-7+Dox. In
H9C2 cells, the same treatment with AN-7 inhibited only
1060.2%, Dox stimulated 1260.4% and AN-7+Dox inhibited
1960.2% of total cellular HDACs activity (Figure 2 D). The effect
of the treatments on cell viability (data not shown) and HDAC 1, 2
and 5 expression (Figure 2 F) was barely discernible after the 2 or
3 h incubation. This is because 2–3 hours is too short a time
period to detect the drugs’ effects on viability or protein
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expression of these enzymes after longer periods of treatment.
Following 23 or 24 h treatments, the viability of 4T1 cells was as
follows: AN-7, 8563.2%, Dox 1460.8% and AN-7+Dox 761.0%
(Figure 2 E). A decrease in the expression of HDACs 1, 2 and 5
was observed in 4T1 cells treated with AN-7 or AN-7+Dox. Since
Dox alone did not affect the expression of these enzymes, the
reduction in HDACs expression in the combination treatment is
due to AN-7 (Figure 2 F). A correlation between AN-7 induced
inhibition of HDAC activity, reduction in HDACs expression and
viability was observed. No correlation between the effect Dox on
HDACs’ activity, expression and viability was found. While Dox
had a detrimental effect on the viability of these cells, it had no
effect the cells’ HDACs activity and expression.
Following 23 or 24 h treatments, the viability of H9C2 cells was:
AN-7, 9961.6%, Dox 5260.8% and AN-7+Dox 6861.2%
(Figure 2E). In these cells AN-7 had no effect on cell viability
and only a minor effect on HDAC activity and expression. Dox
reduced viability and it noticeably increased the HDACs activity
and expression (Figure 2 F). AN-7+Dox as compared to AN-7,
reduced viability (p=0.003), HDACs activity (p=0.004) and
expression. Compared to Dox treatment, the addition of AN-7,
significantly increased viability (p=0.004), reduced the elevated
HDACs activity (p=0.001) and expression.
Figure 1. Effect of Dox, AN-7, and AN-7+Dox in the 4T1 murine mammary carcinoma model. (A) In the preliminary experiment, female
Balb/c mice carrying 75–180 mm
3 subcutaneous 4T1 tumors were randomly divided into three groups (10 mice/group) and were injected ip once a
week with either vehicle, 3 or 5 mg/kg Dox. Tumor volume was measured twice a week up to day 14 when the experiment was terminated (after 2
Dox treatments). Mean6SE of tumor volume was: *p,0.05, untreated vs. the other groups; #p,0.05, Dox 5 mg/kg vs. Dox 3 mg/kg. (B) Mean6SE of
tumor weight and the ratio of heart-weight to body-weight (HW/BW, g/g), measured at the experiment termination point were: *p,0.01, Dox 5 mg/
kg vs. all other groups. (C) In the pivotal experiment, the Percent Failure Free mice bearing 75–180 mm
3 subcutaneous 4T1 tumors, was assessed by a
Kaplan-Mier graph. The mice were assigned to the following treatments: saline vehicle ip (n=7) or po (n=7); ip Dox, 5 mg/kg once/week (n=14); po
AN-7, 50 mg/kg 3 times/week (n=14); po AN-7+ip Dox (n=14). The arrows on the x-axis indicate the point in time of the second and the third Dox
treatment. (D) Mean6SE of heart-weight to body-weight ratios (HW/BW, g/g) at the above experiment end-point was
#p,0.01, Dox 5 mg/kg vs. all
other groups. (E) Tumor weight at the termination point (mean6SE) was: Dox 5 (total) represents the tumor weight of all the mice treated with 5 mg/
kg Dox (n=14), as measured at their individual end-points; Dox 5 (.21) represents the tumor weight of the mice (n=5) treated with 5 mg/kg Dox
and survived beyond day 21 of treatment. *p,0.02 all groups vs. untreated control;
#p,0.05 AN-7+Dox vs. AN-7 or Dox 5 (total) or p,0.01 Dox 5
(.21). (F) Mean6SE of lung lesions for the various treatment groups is shown. *p,0.02, untreated vs. all treatment groups;
#p,0.05, AN-7+Dox vs.
AN-7 or vs. Dox.
doi:10.1371/journal.pone.0031393.g001
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The levels of HDAC-1 and HDAC-2 were 10–15-fold higher
in the tumors than in the hearts (Figure 3). The levels of HDAC-1
and HDAC-2 were unchanged in the tumors of Dox-treated
mice. Whereas, HDAC1 levels decreased 2-fold in the AN-7 and
the AN-7+Dox-treated groups. HDAC2 levels decreased ,5-fold
in the AN-7 group and ,7-fold in the AN-7+Dox-treated group.
In contrast to the downregulation of the HDACs expression by
AN-7 in the tumors, AN-7 and AN-7+Dox did not affect the
expression levels of HDAC1 or HDAC2 in the heart tissue.
Similarly to the observation in vitro, Dox upregulated HDAC-2
by ,4-fold, an effect attenuated by the addition of AN-7 to the
Dox treatment.
Figure 2. Effect of AN-7 on the activity and expression of cellular HDACs classes I and II. (A) The cells were exposed to AN-7 for 3 h in the
presence of the HDAC fluorogenic substrate. The average % of HDAC activity as a function of 0–100 mM concentration of AN-7 of a representative
experiment conducted in quadruplicates is shown. (B) The average IC506SE of AN-7 for each of the cell types is calculated from three independent
experiments. (C) Lysates of cells were loaded (35 mg protein/well) on 10% SDS gels and were subjected to Western blot analysis. HDAC1, HDAC2,
HDAC5 or actin were detected with the appropriate antibodies. (D) HDAC activity of three experiments (in triplicate) conducted with 4T1 (cancer) and
H9C2 (non-cancer) cells treated with AN-7 (50 mM) as a single agent for a total of 3 h, 1 h prior to the addition of the fluorogenic substrate and 2 h in
its presence; Dox (200 nM) as a single agent treatment, or with the combination AN-7+Dox where 50 mM AN-7 was added 1 h prior to the addition of
Dox and the fluorogenic substrate and then incubated for an additional 2 h. (E) The viability of the cells treated as described in (D) was determined by
a Hoechst assay after 23 or 24 h for cells treated with Dox. (F) Cells were treated with AN-7 (3 or 24 h), Dox (2 or 23 h) or AN-7 (3 or 24 h)+Dox (2 or
23 h), as described (D). The lysates of the cells were subjected to Western blot analysis as described (C).
doi:10.1371/journal.pone.0031393.g002
The Selective Anticancer Activity of AN-7
PLoS ONE | www.plosone.org 5 February 2012 | Volume 7 | Issue 2 | e31393Effects of the treatments on viability markers and DNA
damage and repair in vivo
The expression of proteins associated with cell survival and
death were monitored by IHC and or by Western blot analyses.
Cytoplasmic cytochrome-c, a marker of apoptosis, was visible as
positively stained patches in the tumors of mice treated with AN-7
or Dox, in tumors of mice treated with AN-7+Dox the staining was
intensified. In tumors of Dox- and AN-7+Dox-treated mice, in
addition to apoptotic area, necrotic areas (marked with arrows)
were also visible. No detectable levels of cytoplasmic cytochrome-c
or necrosis were found in the tumors of the vehicle-treated mice.
In the hearts, cytoplasmic cytochrome-c was detected only in the
Dox-treated mice. Addition of AN-7 to Dox treatment abrogated
it, demonstrating that AN-7 protects against Dox cardiotoxicity
(Figure 4A).
To assess DNA damage, we evaluated changes in the levels of
cH2AX, a marker of DSBs. In the tumors, all the treatments
induced an increase of cH2AX, however, the greatest increase was
observed after AN-7+Dox treatment (Figure 4B). In the hearts,
Dox increased cH2AX levels significantly as compared to all other
treatments (Figure 4B).
The expression of Rad51, a marker of homologous recombi-
nation-guided DNA repair of DSBs [19], was abundant in the
tumors and scarce in the hearts of vehicle-treated mice. Western
blot analysis and IHC showed that in the tumors, all the
treatments suppressed Rad51 expression, while in the hearts, the
low levels of Rad51 expression was suppressed only by Dox
(Figure 4 C and D). The level of Rad51 expression in the tumors
decreased by AN-72, Dox- and AN-7+Dox treatments by
approximately 3-, 2- and 6- fold, respectively. The effect of the
combined treatment on Rad51 was significantly greater than that
of each of the drugs alone (p#0.03, Figure 4D). These
observations demonstrate that the drugs, in addition to inducing
DNA damage, further intensify this insult by suppressing the
repair mechanism. In cardiac tissue, the addition of AN-7 to Dox
resulted in an increase of Rad51 expression (,8 fold, p=0.0003).
Another protein whose function is maintaining genomic stability
and DNA repair is MRE11 [20]. This protein was expressed in the
hearts of the mice bearing 4T1 tumor, but not in their tumors.
MRE11 basal expression level was similar in the hearts of naı ¨ve,
vehicle-and AN-7 treated mice. Dox treatment downregulated
MRE11 expression by 2- fold and the addition of AN-7 to Dox,
Figure 3. Effect of AN-7, DOX and AN-7+Dox on HDAC1 and HDAC2 expression in tumor or heart. (A) Extracts of tumors from 8 mice and
hearts from 6 mice per treatment group were loaded (20 mg protein/well) on 10% SDS gels, and subjected to Western blot analysis. HDAC1, HDAC2
or actin were detected with the appropriate antibodies. (B) Expression of HDAC1, HDAC2 or actin in tumors and hearts was analyzed by Odyssey 2.1.
The intensity ratio of HDACs to actin (mean6SE) is presented. *p,0.05, tumors of untreated or Dox-treated vs. AN-7 or AN-7+Dox;
#p,0.007, HDAC2
expression in the hearts of Dox treated vs. all other treatment groups.
doi:10.1371/journal.pone.0031393.g003
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PLoS ONE | www.plosone.org 6 February 2012 | Volume 7 | Issue 2 | e31393Figure 4. Effect of AN-7, DOX and their combinations on apoptosis, DNA damage and repair and HO-1. Sections of tumors (left hand-
side) and hearts (right hand-side) from mice were stained with the specified antibodies and counter stained with hematoxylin. For the detection of
markers by Western blot analysis, the samples were resolved on SDS gels. Lysates of tumors (20 mg protein) or hearts (40 mg protein) were loaded on
the gels (left hand-side). Mean6SE of the ratios of bands intensity, each normalized to actin, is shown for tumors (n=7), hearts (n=7) and for 4 hearts
of naive mice (the right hand-side). (A) IHC with anti cytochrome c (Nova Red). The arrows mark the necrotic areas; Bar=200 mm, the 4-fold magnified
picture in the insert was taken from the area indicated by the square. (B) 15% SDS gel stained for cH2AX; (C) IHC with anti Rad51 (DAB); Bar=100 mm,
the 2-fold magnified picture in the insert was taken from the area indicated by the square. (D) 10% SDS gel stained for Rad51 and MRE11; (E) 12% SDS
gel stained for HO-1.
#p,0.05 vs. untreated control; *p,0.05, Dox vs. AN-7 and AN-7+Dox.
doi:10.1371/journal.pone.0031393.g004
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basal level of expression (p=0.001, Figure 4D). Both RAD51 and
MRE11 expression were significantly higher in the hearts of mice
treated with Dox+AN-7 compared to all other treatments. This
observation strongly supports the notion that under stress
conditions, AN-7 imparts its protective activity by inducing
DNA repair pathways.
Effects on HO-1 expression
HO-1 was shown to suppress growth, invasion and migration in
cancer cells, while in the myocardium it confers protection
[12,16]. HO-1 expression was similar in the tumors of vehicle- and
Dox-treated mice, and increased significantly in tumors of the
AN-72 and AN-7+Dox-treated mice (p=0.001 and p=0.03,
respectively). In the heart, HO-1 levels dropped ,2-fold in the
Dox-treated mice compared to the naı ¨ve, vehicle-treated or AN-7-
treated mice (p#0.03). The addition of AN-7 to Dox increased
HO-1 expression ,3-fold compared to Dox treatment alone
(p=0.006). These observations suggest that AN-7 in the
combination treatment induces a protective response against the
oxidative stress imposed by Dox (Figure 4E).
Effect of the treatments on Ki-67, c-Kit, and c-Myc
expression
The high levels of Ki-67 and c-Kit in tumors from untreated
mice, signifying undifferentiated proliferating cell populations,
were substantially reduced after treatment with Dox or AN-7 and
were abrogated after treatment with AN-7+Dox (Figure 5A, B).
In hearts of mice treated with vehicle or AN-7, Ki-67 and c-
Kit expression levels, were similar to the basal expression level
found in naı ¨ve mice. Treatment of mice with Dox alone,
downregulated their expression, whereas, the addition of AN-7
to Dox treatment, elevated Ki-67 and c-Kit expression to the
level which was noticeably higher than their basal expression
level (Figure 5A, B).In the naı ¨ve, vehicle- and AN-72 treated
mice c-Kit positive cells were located mainly in the outer regions
of the ventricular wall, whereas, in AN-7+Dox treated hearts,
foci of c-Kit positive cells were dispersed throughout the
ventricular myocardium.
The protein c-Myc is an important regulator of normal cell
physiology and of tumor cell oncogenic pathways. The normally
high tumor expression of c-Myc was unaffected by Dox but
decreased after AN-7 treatment and further decreased following
AN-7+Dox treatment. The expression of c-Myc was lower in the
hearts than in the tumors, and Dox treatment decreased it further,
whereas AN-7 alone or in combination with Dox increased it
markedly (Figure 5C).
Effect of the treatments on fibrosis
In the tumors stained with Picrosirius red to label fibrous
collagen, extensive fibrosis detected in the vehicle-treated group
was substantially reduced in the Dox- and AN-7-treated groups,
and dramatically diminished following treatment with AN-7+Dox
(Figure 5D). Since interstitial fibrosis plays a vital role in
maintaining the supportive microenviroment of the tumor [21],
its disruption by AN-7, Dox and AN-7+Dox imposes a restriction
on tumor progression.
The hearts were largely negative for Picrosirius red in the naı ¨ve,
vehicle-treated, and AN-7-treated groups. However, in the Dox-
treated group, highly positive staining was visible in the
myocardium indicating interstitial fibrosis, a hallmark of cardio-
myopathy [22]. The response to Dox was attenuated with the
addition of AN-7 to Dox treatment.
Effect of AN-7 or its combination with Dox on
angiogenesis
Low molecular weight fibroblast growth factor-2 (18 kDa, lo-
FGF-2) and vascular endothelial growth factor (VEGF) are potent
angiogenic stimulators [16]. Levels of lo-FGF2, and VEGF were
high in the tumors from the vehicle treated mice (Figure 6A, B).
They decreased after treatment with Dox or AN-7 and were
abrogated after treatment with AN-7+Dox. This suppression
indicates that in the tumors, AN-7 and Dox exerted antiangiogenic
activities that were further intensified by the combination of the
two agents. The upregulation of TSP-1 leads to an inhibitory effect
on tumor angiogenesis that may slow tumor growth [23]. As
shown in Figure 6C, the expression level of TSP-1 was similar in
tumors from the vehicle and Dox-treated mice, increased
significantly in AN-7-treated mice (p=0.03), but increased still
further in the AN-7+Dox treated mice (AN-7 vs. AN-7+Dox,
p=0.01). This suggests that the reduction in angiogenesis in the
tumor is the outcome of a reduction in pro-angiogenic and an
increase in anti-angiogenic factors.
In naı ¨ve and vehicle-treated mice hearts, the expression of the
two angiogenic markers, lo-FGF-2 and VEGF, was indistinguish-
able. It increased with AN-7 treatment, decreased with Dox
treatment, and was restored to normal levels by treating with AN-
7+Dox (Figure 6 A, B).
In line with the angiogenic effect of AN-7 in the heart, the
expression levels of TSP-1 in naı ¨ve, vehicle or AN-7 treated mice,
was similar, whereas in hearts of Dox treated mice there was a
significant increase. The addition of AN-7 to this treatment
significantly reduced the TSP-1 levels. The latter demonstrates
that the addition of AN-7 prevents suppression of angiogenesis by
Dox.
Discussion
Our group previously demonstrated the protective effect of AN-
7 against Dox-toxicity in cardiomyocytes and astrocytes and AN-7
augmentation of Dox’s anticancer activity against breast carcino-
ma and glioblastoma cells in vitro [12,15]. The aim of the present
study was to substantiate our earlier findings in vivo and to
investigate the underlying cellular and molecular modifications
responsible for this disparity. In this study, the tissue-specific
response of AN-7 was supported by the different concomitant
physical and molecular changes that took place in the tumors and
hearts of Balb-c mice bearing sc 4T1 mammary tumors, following
treatments with AN-7, Dox and their combination.
Dox treatment caused a dramatic decrease in mice body weight,
leading to the experimental toxicity endpoint significantly earlier
than in the mice treated with vehicle or AN-7. However, when
AN-7 was added to the Dox treatment, it prolonged the time to
failure of the mice, indicating AN-7’s protective role against Dox-
induced toxicity. At the same time, AN-7 increased the anticancer
efficacy of Dox, as seen by the significantly stronger inhibition of
tumor growth and reduction of lung metastases. Thus, the
combined treatment was more effective than treatment with
either drug alone. The protective effect of AN-7 against Dox-
induced toxicity took place at the same time as its potentiation of
the antineoplastic efficacy of Dox. These findings are consistent
with our previous in vitro studies [12,15]. Since Dox is used to
treat breast cancer and other type of cancers, the AN-7+Dox
combination is potentially beneficial for these protocols [13,14].
Due to AN-7’s dual mode of action in vivo, we consider it a
valuable tool for the investigation of specific molecular events,
which occur concomitantly in the milieu of the normal and in
cancerous tissues.
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HDACs classes I and II and also in the level of expression of
HDAC1, HDAC2 and HDAC5 between non malignant and
malignant cells. The inherent activities of these HDACs in
astrocytes and H9C2 cardiomyoblasts were significantly lower
compared to those found in cancerous cells. AN-7 exhibited a
cell-type-specific inhibition of classes I and II HDAC activity. It
inhibited HDAC activity in U251 and 4T1 cells after 3 h of
treatment to a significantly greater degree than it inhibited this
activity in the immortalized H9C2 or astrocytes. The levels of
HDAC 1, 2, 5 expression in U251 cancer cells did not change
after 3 h of treatment with AN-7, but decreased after 24 h. In
astrocytes and H9C2 cells, AN-7 did not change the level of
expression of these HDACs after 3 or after 24 h of treatment.
Taken together, these data indicate that AN-7 affects the activity
of classes I and II HDACs as well as the expression of
representative members of HDAC class I (HDAC 1, 2) and
HDAC class II (HDAC 5), specifically in cancer cells. In light of
these results, the anticancer efficacy and the selectivity of AN-7
may be ascribed to its specific suppression of HDACs activity and
Figure 5. Effect of AN-7, DOX and their combinations on markers of proliferation and fibrosis. Sections of tumors and hearts were
stained (DAB) for: (A) Ki-67; (B) c-Kit and both were counter stained with hematoxylin. The arrowhead marked the c-Kit positively staind cells.
Bar=200 mm, the 4-fold magnified picture in the insert was taken from the area indicated by the square. (C) Lysates samples, as described above,
were resolved on 10% SDS gel and stained for c-Myc (left). The Mean6SE ratio of c-Myc/actin expression is shown (right).
#p,0.05, as specified, vs.
untreated control; *p,0.05, as specified, vs Dox. (D) Picrosirius red and fast-green for the visualization of interstitial fibrosis. Bar=200 mm, the 2-fold
magnified picture in the insert was taken from the area indicated by the square.
doi:10.1371/journal.pone.0031393.g005
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activity in the different cell types. These results substantiate the
notion that AN-7 specifically targets the elevated HDACs
activities and expression in cancer cells.
Correspondingly, the 10–15-fold lower levels of HDAC1 and
HDAC2 in the hearts compared to the 4T1 tumors were
unaffected by Dox but were suppressed by AN-7 and AN-
7+Dox. These observations are in accordance with reports that
high levels of class I HDACs are expressed in tumors [24]. Since
the high level of HDACs expression play a role in sustaining the
oncogenic state and correlate with disease aggressiveness
[25,26,27], we may infer that AN-7 exerts its anti-cancer activity,
at least in part, by downregulating the activity and expression of
HDACs in the tumors.
Although AN-7 treatment alone did not affect HDAC
expression in the myocardium, when it was added to Dox, it
negated the Dox-induced increase in HDAC-2 expression. This
apparent discrepancy (seen also in vitro) may be explained by
reports that the activation of HDAC-2, but not HDAC-1, plays a
critical role in the development of cardiac toxicity [3,28]. Thus,
AN-7 downregulation of HDAC-2 expression may be part of the
mechanism whereby it protects cardiac cells against Dox [29].
Altogether, these findings support the notion that the discrim-
inatory effect of AN-7 stems also from its ability to affect the
HDAC expression and activity in a cell-type specific manner. The
caveat is that this conclusion is based on the examination of only
classes I and II out of the four known classes of HDACs [27]. The
relevance of distinct HDAC repertoires to the specificity of AN-7
action in normal and cancerous tissues remains to be further
studied.
The interplay among the pro- and anti- survival and angiogenic
factors in the tumor and the myocardium showed tissue selective
differences. Dox induces formation of DNA DSBs by elevating
cellular ROS levels, intercalation into the DNA, the formation of
Dox-DNA adducts, and by poisoning the transient topoisomerase
II-DNA intermediate formed during transcription and replication
[30,31,32]. In cancer cells, the AN-7 induction of ROS probably
leads to DSBs formation and when added to Dox, the effect is
further enhanced [12].
In response to DSBs formation, cH2AX accumulates on the site
and interacts with a multi-protein complex that activates a repair-
control response involving Rad51 and MRE11 [20,33]. An
effective repair pathway is associated with cell survival, and
conversely, a repressed pathway leads to cell death. We found that
Figure 6. Effect of AN-7, DOX and their combinations on angiogenesis. Sections of tumors and hearts were stained for (A) lo-FGF (DAB); (B)
VEGF (Nova Red) and counter stained with hematoxylin. Bar=200 mm, the 4-fold magnified picture in the insert was taken from the area indicated by
the square. (C) Lysates samples (as described above) were resolved on 7.5% SDS gels and stained for TSP-1(left). Mean6SE of the ratio of TSP-1/actin
expression is shown (right),
#p,0.05, as specified, vs. untreated control; * p,0.05, as specified, vs. Dox;
&p,0.05, AN-7+Dox vs. AN-7.
doi:10.1371/journal.pone.0031393.g006
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7+Dox simultaneously increases DNA damage and decreases
DNA repair, leading to cancer cell mortality, as manifested by the
increased levels of cytoplasmic cytochrome-c.
In the hearts, Dox treatment induced the expression of cH2AX
and reduced the expression of Rad51 and MRE11, thereby
suppressing DNA DSBs repair causing the release of cytochrome c
to the cytoplasm thus leading to cell death. AN-7 alone had no
myocardial cell damage, but its addition to Dox, concurrently
decreased the DNA damage and increased the DNA repair,
thereby, negating the release of cytoplasmic cytochrome-c. This
sequence of events contributes to the protective effect of AN-7
against Dox cardiotoxicity, and is in agreement with our previous
studies [12,15].
AN-7+Dox treatment led to opposing changes in the DNA
damage-response mechanism within the tumor and the heart of
the same mice. In the tumor, the DNA damage was intensified and
the DNA repair was suppressed, culminating in cell death.
Conversely, in the heart, DNA damage was decreased and DNA
repair was enhanced, preserving the viability of the cells in the
heart. As mentioned above, we attribute the cell specificity of AN-
7 to its inhibitory effect on distinct HDACs. This is consistent with
recent reports demonstrating the involvement of histone selective
acetylation in the activation of DNA repair [34,35]. Taken
together, the opposing effects of AN-7 in the tumor and the heart
infer that DNA damage and response mechanism are selectively
targeted by AN-7.
HO-1 has been shown to inhibit cancer cell proliferation and
reduce tumor invasiveness [36]. In the present study, AN-7 and
AN-7+Dox caused a significantly greater increase in HO-1
expression than Dox alone, suggesting that increased HO-1
expression is one of the molecular changes involved in the anti-
proliferative and anti- metastatic activities of these treatments.
In the heart, HO-1 functions under stress conditions, when it
rapidly degrades pro-oxidant heme to carbon monoxide (CO) and
biliverdin/bilirubin. CO inhibits inflammation and oxidative-
stress [37], and the biliverdin/bilirubin reduces oxidative activity
of the released Fe
2+ [38]. Together, these events result in
protection of the heart [39]. We found that treatment with AN-
7+Dox significantly increases HO-1 expression compared to Dox
alone, suggesting that AN-7+Dox induces a defensive response
against the oxidative stress and inflammation imposed by Dox.
These observations are in line with our earlier findings that AN-7
reduced the elevation of ROS in cardiomyocytes, and of TNF-a
and interferon-c in the heart and plasma of mice treated with a
high dose of Dox [12].
Fibrosis in tumors provides the supportive extracellular matrix
that is secreted by activated myofibroblasts [21]. Growth factors
secreted by cancer associated fibroblasts, stimulate tumor cell
proliferation and increase angiogenesis and tumor cell invasion
[40,41]. Fibroblasts were shown to be key modulators of immune
polarization in the tumor microenvironment of the 4T1 murine
model and therefore, are proposed to be valid targets for
metastatic breast cancer therapy [42]. In an earlier study, we
demonstrated that AN-7 inhibited the migration of prostate cell
lines and the metastasis and angiogenesis of prostate tumors to the
lungs and the bone-marrow [8,10]. In the present study, we
demonstrate that treatment of tumor-bearing mice with AN-
7+Dox, as compared to each drug alone, dramatically decreases
the abundance of the fibroblasts in the tumor. This was
accompanied by a reduced deposition of collagen and a
suppression of angiogenesis. This was achieved by a reduction in
pro-angiogenic factors and an increase of anti-angiogenic factor
(TSP-1), thereby limiting the capacity of the tumor to grow.
Previously, we have shown that the viability of cardiofibroblasts
was dramatically repressed by AN-7+Dox, suggesting that in the
heart, AN-7 may attenuate Dox-induced fibrosis [12]. Heart
fibrosis is a classical feature of tissue remodeling in a response to a
variety of pathological conditions. Heart fibrosis is characterized
by the expansion of the extracellular matrix and in particular the
accumulation of collagen type I [22]. HDACIs were reported to
reduce the deposition of fibrotic extracellular matrix by inhibiting
myofibroblast proliferation [41,43]. The above is supported by our
present study that unequivocally demonstrates that the addition of
AN-7 to Dox treatment negates Dox-induced fibrosis in the heart.
This finding has important implications for the preservation of the
heart elasticity and contractility. Taken together, cancer associated
fibroblasts and the cardiofibroblasts are another target of AN-7
activity.
The protein Ki-67 is a marker for cancer and normal cell
proliferation [44]. The tyrosine kinase receptor c-Kit activates
downstream pathways leading to cell proliferation and survival
[45]. Overexpression of c-Kit in tumors points to the presence of
cancer stem cells and predicts treatment resistance and poor
outcomes. Therefore, disruption of c-Kit expression in c-Kit-
driven tumors represents a promising therapeutic approach
[46,47]. In this study we demonstrated that both Dox and AN-7
substantially reduce Ki-67 and c-Kit expression in the tumor and
AN-7+Dox abolish it, supporting the notion that the combination
treatment can potentially benefit treatment-resistance and aggres-
sive tumors.
In the heart, Ki-67 and c-Kit were shown to be expressed by
cardiac progenitor cells (CPC) residing mainly in the epicardium
[48,49]. In the present study, the prevalence of Ki-67 and c-Kit
expressing cells in the naı ¨ve, vehicle and AN-7 treated hearts, was
similar. The change in locality of the c-Kit positive cells is
noteworthy. In naı ¨ve, vehicle and AN-7- treated mice, they resided
mostly in the outer regions of the myocardium. Following Dox
treatment their expression was diminished and with the addition of
AN-7 to Dox, their expression was restored as foci distributed
throughout the myocardium. These foci may be regeneration sites
repopulated with CPCs. Since treatment with Dox was reported to
induce CPC death, AN-7 protection of the c-Kit positive cells is
likely to preserve the CPCs and therefore the cardio-regeneration
capacity [48,50,51]. Angelis et al. suggested that Dox-induced
depletion of the CPC pool within the myocardium contributes to
the dramatic manifestation of heart failure in animal models and
humans due to the diminished regenerative capacity of their hearts
[51]. Patients, who survive cancer treatment with Dox, face the
risk of developing heart failure, either soon after treatment or later
in life. Therefore, the addition of AN-7 to Dox treatment is a
promising approach to the reduction of cardiac complications in
these patients.
The protein c-Myc is aberrantly overexpressed in more than
30% of all cancers, including 4T1 cells [52]. In the 4T1 tumors, its
expression was unaffected by Dox, significantly downregulated by
AN-7 and suppressed further by AN-7+Dox. The repression of c-
Myc is associated with anti-angiogenic effects marked by an
increased expression of the potent angiogenesis inhibitor TSP-1,
repression of the pro-angiogenesis factors, lo-FGF-2, and VEGF.
TSP-1 acts as a scavenger of matrix-associated angiogenic factors
and is repressed by c-Myc, which upregulates its repressor miR17-
92 [53,54]. On the basis of these findings, we propose that the
suppression of c-Myc plays a central role in the inhibition of tumor
angiogenesis.
Coupled to these changes, the myocardial c-Myc expression
increased significantly by AN-7 alone and decreased with Dox
treatment. The addition of AN-7 to Dox treatment reversed the
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Myc-regulated angiogenesis inhibitor, was unaffected by AN-7 and
increased by Dox. The addition of AN-7 to Dox treatment
relieved the myocardium from TSP-1 angiogenic repression, as
was seen by co-elevation in the expression of lo-FGF-2 and VEGF.
These observations indicate that AN-7 also elicits its cardiopro-
tective activity by increasing pro-angiogenic factors in the heart.
Collectively, our findings support the notion that AN-7 affects
cancer and normal cells differently. Moreover, we have shown that
in addition to disparately affecting HDACs activity and expres-
sion, AN-7 and AN-7 in combination with Dox, distinctively
modulated major molecular and cellular events affecting cell
survival.
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